Demethylating Agent 5-Aza-2′-Deoxycytidine Enhances Susceptibility of Renal Cell Carcinoma to Paclitaxel
- 31 May 2007
- Vol. 69 (5) , 1007-1012
- https://doi.org/10.1016/j.urology.2007.02.026
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 20 references indexed in Scilit:
- Interferon alpha 2b as Medical Selection for Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma: A Consecutive StudyEuropean Urology, 2005
- Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2′-deoxycytidine treatment is associated with activation of the interferon signalling pathwayOncogene, 2005
- The In vitro and In vivo Effects of Re-Expressing Methylated von Hippel-Lindau Tumor Suppressor Gene in Clear Cell Renal Carcinoma with 5-Aza-2′-deoxycytidineClinical Cancer Research, 2004
- Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesisOncogene, 2004
- 5-aza-2′-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cellsOncogene, 2004
- 5-Aza-2′-deoxycytidine Activates the p53/p21Waf1/Cip1 Pathway to Inhibit Cell ProliferationJournal of Biological Chemistry, 2004
- Multigene methylation analysis of Wilms' tumour and adult renal cell carcinomaOncogene, 2003
- Prognostic factors in renal cell carcinomaBritish Journal of Urology, 1995
- Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell cancerEuropean Journal Of Cancer, 1993
- Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alphaEuropean Journal Of Cancer, 1992